Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 461

1.

The INTUIT Study: Investigating Neuroinflammation Underlying Postoperative Cognitive Dysfunction.

Berger M, Oyeyemi D, Olurinde MO, Whitson HE, Weinhold KJ, Woldorff MG, Lipsitz LA, Moretti E, Giattino CM, Roberts KC, Zhou J, Bunning T, Ferrandino M, Scheri RP, Cooter M, Chan C, Cabeza R, Browndyke JN, Murdoch DM, Devinney MJ, Shaw LM, Cohen HJ, Mathew JP; INTUIT Investigators.

J Am Geriatr Soc. 2019 Jan 23. doi: 10.1111/jgs.15770. [Epub ahead of print]

PMID:
30674067
2.

Early increase of CSF sTREM2 in Alzheimer's disease is associated with tau related-neurodegeneration but not with amyloid-β pathology.

Suárez-Calvet M, Morenas-Rodríguez E, Kleinberger G, Schlepckow K, Araque Caballero MÁ, Franzmeier N, Capell A, Fellerer K, Nuscher B, Eren E, Levin J, Deming Y, Piccio L, Karch CM, Cruchaga C, Shaw LM, Trojanowski JQ, Weiner M, Ewers M, Haass C; Alzheimer’s Disease Neuroimaging Initiative.

Mol Neurodegener. 2019 Jan 10;14(1):1. doi: 10.1186/s13024-018-0301-5.

3.

The Parkinson's progression markers initiative (PPMI) - establishing a PD biomarker cohort.

Marek K, Chowdhury S, Siderowf A, Lasch S, Coffey CS, Caspell-Garcia C, Simuni T, Jennings D, Tanner CM, Trojanowski JQ, Shaw LM, Seibyl J, Schuff N, Singleton A, Kieburtz K, Toga AW, Mollenhauer B, Galasko D, Chahine LM, Weintraub D, Foroud T, Tosun-Turgut D, Poston K, Arnedo V, Frasier M, Sherer T; Parkinson's Progression Markers Initiative.

Ann Clin Transl Neurol. 2018 Oct 31;5(12):1460-1477. doi: 10.1002/acn3.644. eCollection 2018 Dec.

4.

Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders.

Olsson B, Portelius E, Cullen NC, Sandelius Å, Zetterberg H, Andreasson U, Höglund K, Irwin DJ, Grossman M, Weintraub D, Chen-Plotkin A, Wolk D, McCluskey L, Elman L, Shaw LM, Toledo JB, McBride J, Hernandez-Con P, Lee VM, Trojanowski JQ, Blennow K.

JAMA Neurol. 2018 Dec 3. doi: 10.1001/jamaneurol.2018.3746. [Epub ahead of print]

PMID:
30508027
5.

Current state of Alzheimer's fluid biomarkers.

Molinuevo JL, Ayton S, Batrla R, Bednar MM, Bittner T, Cummings J, Fagan AM, Hampel H, Mielke MM, Mikulskis A, O'Bryant S, Scheltens P, Sevigny J, Shaw LM, Soares HD, Tong G, Trojanowski JQ, Zetterberg H, Blennow K.

Acta Neuropathol. 2018 Dec;136(6):821-853. doi: 10.1007/s00401-018-1932-x. Epub 2018 Nov 28. Review.

6.

CSF progranulin increases in the course of Alzheimer's disease and is associated with sTREM2, neurodegeneration and cognitive decline.

Suárez-Calvet M, Capell A, Araque Caballero MÁ, Morenas-Rodríguez E, Fellerer K, Franzmeier N, Kleinberger G, Eren E, Deming Y, Piccio L, Karch CM, Cruchaga C, Paumier K, Bateman RJ, Fagan AM, Morris JC, Levin J, Danek A, Jucker M, Masters CL, Rossor MN, Ringman JM, Shaw LM, Trojanowski JQ, Weiner M, Ewers M, Haass C; Dominantly Inherited Alzheimer Network; Alzheimer's Disease Neuroimaging Initiative.

EMBO Mol Med. 2018 Dec;10(12). pii: e9712. doi: 10.15252/emmm.201809712.

7.

Derivation of cutoffs for the Elecsys® amyloid β (1-42) assay in Alzheimer's disease.

Shaw LM, Waligorska T, Fields L, Korecka M, Figurski M, Trojanowski JQ, Eichenlaub U, Wahl S, Quan M, Pontecorvo MJ, Lachno DR, Talbot JA, Andersen SW, Siemers ER, Dean RA.

Alzheimers Dement (Amst). 2018 Aug 11;10:698-705. doi: 10.1016/j.dadm.2018.07.002. eCollection 2018.

8.

Distinct White Matter Changes Associated with Cerebrospinal Fluid Amyloid-β1-42 and Hypertension.

Al-Janabi OM, Brown CA, Bahrani AA, Abner EL, Barber JM, Gold BT, Goldstein LB, Murphy RR, Nelson PT, Johnson NF, Shaw LM, Smith CD, Trojanowski JQ, Wilcock DM, Jicha GA.

J Alzheimers Dis. 2018;66(3):1095-1104. doi: 10.3233/JAD-180663.

PMID:
30400099
9.

Altered bile acid profile in mild cognitive impairment and Alzheimer's disease: Relationship to neuroimaging and CSF biomarkers.

Nho K, Kueider-Paisley A, MahmoudianDehkordi S, Arnold M, Risacher SL, Louie G, Blach C, Baillie R, Han X, Kastenmüller G, Jia W, Xie G, Ahmad S, Hankemeier T, van Duijn CM, Trojanowski JQ, Shaw LM, Weiner MW, Doraiswamy PM, Saykin AJ, Kaddurah-Daouk R; Alzheimer's Disease Neuroimaging Initiative and the Alzheimer Disease Metabolomics Consortium.

Alzheimers Dement. 2019 Feb;15(2):232-244. doi: 10.1016/j.jalz.2018.08.012. Epub 2018 Oct 15.

PMID:
30337152
10.

Altered bile acid profile associates with cognitive impairment in Alzheimer's disease-An emerging role for gut microbiome.

MahmoudianDehkordi S, Arnold M, Nho K, Ahmad S, Jia W, Xie G, Louie G, Kueider-Paisley A, Moseley MA, Thompson JW, St John Williams L, Tenenbaum JD, Blach C, Baillie R, Han X, Bhattacharyya S, Toledo JB, Schafferer S, Klein S, Koal T, Risacher SL, Kling MA, Motsinger-Reif A, Rotroff DM, Jack J, Hankemeier T, Bennett DA, De Jager PL, Trojanowski JQ, Shaw LM, Weiner MW, Doraiswamy PM, van Duijn CM, Saykin AJ, Kastenmüller G, Kaddurah-Daouk R; Alzheimer's Disease Neuroimaging Initiative and the Alzheimer Disease Metabolomics Consortium.

Alzheimers Dement. 2019 Jan;15(1):76-92. doi: 10.1016/j.jalz.2018.07.217. Epub 2018 Oct 15.

11.

Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative.

Veitch DP, Weiner MW, Aisen PS, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack CR Jr, Jagust W, Morris JC, Petersen RC, Saykin AJ, Shaw LM, Toga AW, Trojanowski JQ; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2019 Jan;15(1):106-152. doi: 10.1016/j.jalz.2018.08.005. Epub 2018 Oct 13. Review.

PMID:
30321505
12.

Elevated CSF GAP-43 is Alzheimer's disease specific and associated with tau and amyloid pathology.

Sandelius Å, Portelius E, Källén Å, Zetterberg H, Rot U, Olsson B, Toledo JB, Shaw LM, Lee VMY, Irwin DJ, Grossman M, Weintraub D, Chen-Plotkin A, Wolk DA, McCluskey L, Elman L, Kostanjevecki V, Vandijck M, McBride J, Trojanowski JQ, Blennow K.

Alzheimers Dement. 2019 Jan;15(1):55-64. doi: 10.1016/j.jalz.2018.08.006. Epub 2018 Oct 12.

13.

Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease.

Shaw LM, Arias J, Blennow K, Galasko D, Molinuevo JL, Salloway S, Schindler S, Carrillo MC, Hendrix JA, Ross A, Illes J, Ramus C, Fifer S.

Alzheimers Dement. 2018 Nov;14(11):1505-1521. doi: 10.1016/j.jalz.2018.07.220. Epub 2018 Oct 10. Review.

14.

FLOWERING LOCUS T2 regulates spike development and fertility in temperate cereals.

Shaw LM, Lyu B, Turner R, Li C, Chen F, Han X, Fu D, Dubcovsky J.

J Exp Bot. 2019 Jan 1;70(1):193-204. doi: 10.1093/jxb/ery350.

15.

Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease.

Gangishetti U, Christina Howell J, Perrin RJ, Louneva N, Watts KD, Kollhoff A, Grossman M, Wolk DA, Shaw LM, Morris JC, Trojanowski JQ, Fagan AM, Arnold SE, Hu WT.

Alzheimers Res Ther. 2018 Sep 25;10(1):98. doi: 10.1186/s13195-018-0426-3.

16.

Antibody-based methods for the measurement of α-synuclein concentration in human cerebrospinal fluid - method comparison and round robin study.

Mollenhauer B, Bowman FD, Drake D, Duong J, Blennow K, El-Agnaf O, Shaw LM, Masucci J, Taylor P, Umek RM, Dunty JM, Smith CL, Stoops E, Vanderstichele H, Schmid AW, Moniatte M, Zhang J, Kruse N, Lashuel HA, Teunissen C, Schubert T, Dave KD, Hutten SJ, Zetterberg H.

J Neurochem. 2018 Aug 20. doi: 10.1111/jnc.14569. [Epub ahead of print]

PMID:
30125936
17.

Cerebrospinal fluid tau, Aβ, and sTREM2 in Former National Football League Players: Modeling the relationship between repetitive head impacts, microglial activation, and neurodegeneration.

Alosco ML, Tripodis Y, Fritts NG, Heslegrave A, Baugh CM, Conneely S, Mariani M, Martin BM, Frank S, Mez J, Stein TD, Cantu RC, McKee AC, Shaw LM, Trojanowski JQ, Blennow K, Zetterberg H, Stern RA.

Alzheimers Dement. 2018 Sep;14(9):1159-1170. doi: 10.1016/j.jalz.2018.05.004. Epub 2018 Jul 23.

PMID:
30049650
18.

Sex-specific genetic predictors of Alzheimer's disease biomarkers.

Deming Y, Dumitrescu L, Barnes LL, Thambisetty M, Kunkle B, Gifford KA, Bush WS, Chibnik LB, Mukherjee S, De Jager PL, Kukull W, Huentelman M, Crane PK, Resnick SM, Keene CD, Montine TJ, Schellenberg GD, Haines JL, Zetterberg H, Blennow K, Larson EB, Johnson SC, Albert M, Moghekar A, Del Aguila JL, Fernandez MV, Budde J, Hassenstab J, Fagan AM, Riemenschneider M, Petersen RC, Minthon L, Chao MJ, Van Deerlin VM, Lee VM, Shaw LM, Trojanowski JQ, Peskind ER, Li G, Davis LK, Sealock JM, Cox NJ; Alzheimer’s Disease Neuroimaging Initiative (ADNI); Alzheimer Disease Genetics Consortium (ADGC), Goate AM, Bennett DA, Schneider JA, Jefferson AL, Cruchaga C, Hohman TJ.

Acta Neuropathol. 2018 Dec;136(6):857-872. doi: 10.1007/s00401-018-1881-4. Epub 2018 Jul 2.

PMID:
29967939
19.

The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review.

Hansson O, Mikulskis A, Fagan AM, Teunissen C, Zetterberg H, Vanderstichele H, Molinuevo JL, Shaw LM, Vandijck M, Verbeek MM, Savage M, Mattsson N, Lewczuk P, Batrla R, Rutz S, Dean RA, Blennow K.

Alzheimers Dement. 2018 Oct;14(10):1313-1333. doi: 10.1016/j.jalz.2018.05.008. Epub 2018 Jun 23. Review.

PMID:
29940161
20.

Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology.

Portelius E, Olsson B, Höglund K, Cullen NC, Kvartsberg H, Andreasson U, Zetterberg H, Sandelius Å, Shaw LM, Lee VMY, Irwin DJ, Grossman M, Weintraub D, Chen-Plotkin A, Wolk DA, McCluskey L, Elman L, McBride J, Toledo JB, Trojanowski JQ, Blennow K.

Acta Neuropathol. 2018 Sep;136(3):363-376. doi: 10.1007/s00401-018-1851-x. Epub 2018 Apr 26.

21.

Identification of a Novel Invasion-Promoting Region in Insulin Receptor Substrate 2.

Mercado-Matos J, Janusis J, Zhu S, Chen SS, Shaw LM.

Mol Cell Biol. 2018 Jun 28;38(14). pii: e00590-17. doi: 10.1128/MCB.00590-17. Print 2018 Jul 15.

22.

IRS2 mutations linked to invasion in pleomorphic invasive lobular carcinoma.

Zhu S, Ward BM, Yu J, Matthew-Onabanjo AN, Janusis J, Hsieh CC, Tomaszewicz K, Hutchinson L, Zhu LJ, Kandil D, Shaw LM.

JCI Insight. 2018 Apr 19;3(8). pii: 97398. doi: 10.1172/jci.insight.97398. [Epub ahead of print]

23.

Cerebrospinal fluid α-synuclein contributes to the differential diagnosis of Alzheimer's disease.

Shi M, Tang L, Toledo JB, Ginghina C, Wang H, Aro P, Jensen PH, Weintraub D, Chen-Plotkin AS, Irwin DJ, Grossman M, McCluskey L, Elman LB, Wolk DA, Lee EB, Shaw LM, Trojanowski JQ, Zhang J.

Alzheimers Dement. 2018 Aug;14(8):1052-1062. doi: 10.1016/j.jalz.2018.02.015. Epub 2018 Mar 28.

PMID:
29604263
24.

Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort.

Simuni T, Siderowf A, Lasch S, Coffey CS, Caspell-Garcia C, Jennings D, Tanner CM, Trojanowski JQ, Shaw LM, Seibyl J, Schuff N, Singleton A, Kieburtz K, Toga AW, Mollenhauer B, Galasko D, Chahine LM, Weintraub D, Foroud T, Tosun D, Poston K, Arnedo V, Frasier M, Sherer T, Chowdhury S, Marek K; Parkinson's Progression Marker Initiative*.

Mov Disord. 2018 May;33(5):771-782. doi: 10.1002/mds.27361. Epub 2018 Mar 23.

25.

A 2-Step Cerebrospinal Algorithm for the Selection of Frontotemporal Lobar Degeneration Subtypes.

Lleó A, Irwin DJ, Illán-Gala I, McMillan CT, Wolk DA, Lee EB, Van Deerlin VM, Shaw LM, Trojanowski JQ, Grossman M.

JAMA Neurol. 2018 Jun 1;75(6):738-745. doi: 10.1001/jamaneurol.2018.0118.

PMID:
29554190
26.

The technical reliability and biotemporal stability of cerebrospinal fluid biomarkers for profiling multiple pathophysiologies in Alzheimer's disease.

Trombetta BA, Carlyle BC, Koenig AM, Shaw LM, Trojanowski JQ, Wolk DA, Locascio JJ, Arnold SE.

PLoS One. 2018 Mar 5;13(3):e0193707. doi: 10.1371/journal.pone.0193707. eCollection 2018.

27.

Measurements of auto-antibodies to α-synuclein in the serum and cerebral spinal fluids of patients with Parkinson's disease.

Akhtar RS, Licata JP, Luk KC, Shaw LM, Trojanowski JQ, Lee VM.

J Neurochem. 2018 Jun;145(6):489-503. doi: 10.1111/jnc.14330. Epub 2018 Jun 10.

PMID:
29500813
28.

CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts.

Hansson O, Seibyl J, Stomrud E, Zetterberg H, Trojanowski JQ, Bittner T, Lifke V, Corradini V, Eichenlaub U, Batrla R, Buck K, Zink K, Rabe C, Blennow K, Shaw LM; Swedish BioFINDER study group; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2018 Nov;14(11):1470-1481. doi: 10.1016/j.jalz.2018.01.010. Epub 2018 Mar 1.

29.

CSF tau and β-amyloid predict cerebral synucleinopathy in autopsied Lewy body disorders.

Irwin DJ, Xie SX, Coughlin D, Nevler N, Akhtar RS, McMillan CT, Lee EB, Wolk DA, Weintraub D, Chen-Plotkin A, Duda JE, Spindler M, Siderowf A, Hurtig HI, Shaw LM, Grossman M, Trojanowski JQ.

Neurology. 2018 Mar 20;90(12):e1038-e1046. doi: 10.1212/WNL.0000000000005166. Epub 2018 Feb 21.

PMID:
29467305
30.

A Longitudinal Study of Total and Phosphorylated α-Synuclein with Other Biomarkers in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment.

Wang H, Stewart T, Toledo JB, Ginghina C, Tang L, Atik A, Aro P, Shaw LM, Trojanowski JQ, Galasko DR, Edland S, Jensen PH, Shi M, Zhang J; Alzheimer’s Disease Neuroimaging Initiative.

J Alzheimers Dis. 2018;61(4):1541-1553. doi: 10.3233/JAD-171013.

31.

Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting.

Walsh RR, Krismer F, Galpern WR, Wenning GK, Low PA, Halliday G, Koroshetz WJ, Holton J, Quinn NP, Rascol O, Shaw LM, Eidelberg D, Bower P, Cummings JL, Abler V, Biedenharn J, Bitan G, Brooks DJ, Brundin P, Fernandez H, Fortier P, Freeman R, Gasser T, Hewitt A, Höglinger GU, Huentelman MJ, Jensen PH, Jeromin A, Kang UJ, Kaufmann H, Kellerman L, Khurana V, Klockgether T, Kim WS, Langer C, LeWitt P, Masliah E, Meissner W, Melki R, Ostrowitzki S, Piantadosi S, Poewe W, Robertson D, Roemer C, Schenk D, Schlossmacher M, Schmahmann JD, Seppi K, Shih L, Siderowf A, Stebbins GT, Stefanova N, Tsuji S, Sutton S, Zhang J.

Neurology. 2018 Jan 9;90(2):74-82. doi: 10.1212/WNL.0000000000004798. Epub 2017 Dec 13. Review.

32.

Neocortical origin and progression of gray matter atrophy in nonamnestic Alzheimer's disease.

Phillips JS, Da Re F, Dratch L, Xie SX, Irwin DJ, McMillan CT, Vaishnavi SN, Ferrarese C, Lee EB, Shaw LM, Trojanowski JQ, Wolk DA, Grossman M.

Neurobiol Aging. 2018 Mar;63:75-87. doi: 10.1016/j.neurobiolaging.2017.11.008. Epub 2017 Nov 21.

PMID:
29223682
33.

Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features.

Goldman JG, Andrews H, Amara A, Naito A, Alcalay RN, Shaw LM, Taylor P, Xie T, Tuite P, Henchcliffe C, Hogarth P, Frank S, Saint-Hilaire MH, Frasier M, Arnedo V, Reimer AN, Sutherland M, Swanson-Fischer C, Gwinn K; Fox Investigation of New Biomarker Discovery, Kang UJ.

Mov Disord. 2018 Feb;33(2):282-288. doi: 10.1002/mds.27232. Epub 2017 Dec 4.

34.

The Effect of Propofol vs. Isoflurane Anesthesia on Postoperative Changes in Cerebrospinal Fluid Cytokine Levels: Results from a Randomized Trial.

Berger M, Ponnusamy V, Greene N, Cooter M, Nadler JW, Friedman A, McDonagh DL, Laskowitz DT, Newman MF, Shaw LM, Warner DS, Mathew JP, James ML; MAD-PIA Investigators.

Front Immunol. 2017 Nov 13;8:1528. doi: 10.3389/fimmu.2017.01528. eCollection 2017.

35.

APOE, thought disorder, and SPARE-AD predict cognitive decline in established Parkinson's disease.

Tropea TF, Xie SX, Rick J, Chahine LM, Dahodwala N, Doshi J, Davatzikos C, Shaw LM, Van Deerlin V, Trojanowski JQ, Weintraub D, Chen-Plotkin AS.

Mov Disord. 2018 Feb;33(2):289-297. doi: 10.1002/mds.27204. Epub 2017 Nov 23.

36.

Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry.

Lewczuk P, Riederer P, O'Bryant SE, Verbeek MM, Dubois B, Visser PJ, Jellinger KA, Engelborghs S, Ramirez A, Parnetti L, Jack CR Jr, Teunissen CE, Hampel H, Lleó A, Jessen F, Glodzik L, de Leon MJ, Fagan AM, Molinuevo JL, Jansen WJ, Winblad B, Shaw LM, Andreasson U, Otto M, Mollenhauer B, Wiltfang J, Turner MR, Zerr I, Handels R, Thompson AG, Johansson G, Ermann N, Trojanowski JQ, Karaca I, Wagner H, Oeckl P, van Waalwijk van Doorn L, Bjerke M, Kapogiannis D, Kuiperij HB, Farotti L, Li Y, Gordon BA, Epelbaum S, Vos SJB, Klijn CJM, Van Nostrand WE, Minguillon C, Schmitz M, Gallo C, Lopez Mato A, Thibaut F, Lista S, Alcolea D, Zetterberg H, Blennow K, Kornhuber J; Members of the WFSBP Task Force Working on this Topic: Peter Riederer, Carla Gallo, Dimitrios Kapogiannis, Andrea Lopez Mato, Florence Thibaut.

World J Biol Psychiatry. 2018 Jun;19(4):244-328. doi: 10.1080/15622975.2017.1375556. Epub 2017 Oct 27. Review.

PMID:
29076399
37.

Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls.

Mollenhauer B, Caspell-Garcia CJ, Coffey CS, Taylor P, Shaw LM, Trojanowski JQ, Singleton A, Frasier M, Marek K, Galasko D; Parkinson's Progression Marker Initiative.

Neurology. 2017 Nov 7;89(19):1959-1969. doi: 10.1212/WNL.0000000000004609. Epub 2017 Oct 13.

38.

Targeted neurogenesis pathway-based gene analysis identifies ADORA2A associated with hippocampal volume in mild cognitive impairment and Alzheimer's disease.

Horgusluoglu-Moloch E, Nho K, Risacher SL, Kim S, Foroud T, Shaw LM, Trojanowski JQ, Aisen PS, Petersen RC, Jack CR Jr, Lovestone S, Simmons A, Weiner MW, Saykin AJ; Alzheimer's Disease Neuroimaging Initiative (ADNI).

Neurobiol Aging. 2017 Dec;60:92-103. doi: 10.1016/j.neurobiolaging.2017.08.010. Epub 2017 Aug 18.

39.

A user's guide for α-synuclein biomarker studies in biological fluids: Perianalytical considerations.

Mollenhauer B, Batrla R, El-Agnaf O, Galasko DR, Lashuel HA, Merchant KM, Shaw LM, Selkoe DJ, Umek R, Vanderstichele H, Zetterberg H, Zhang J, Caspell-Garcia C, Coffey C, Hutten SJ, Frasier M, Taylor P; Investigating Synuclein Consortium of the Michael J. Fox Foundation for Parkinson's Research.

Mov Disord. 2017 Aug;32(8):1117-1130. doi: 10.1002/mds.27090. Epub 2017 Jul 22. Review.

40.

Clinically silent Alzheimer's and vascular pathologies influence brain networks supporting executive function in healthy older adults.

Gold BT, Brown CA, Hakun JG, Shaw LM, Trojanowski JQ, Smith CD.

Neurobiol Aging. 2017 Oct;58:102-111. doi: 10.1016/j.neurobiolaging.2017.06.012. Epub 2017 Jun 24.

41.

Ante mortem cerebrospinal fluid tau levels correlate with postmortem tau pathology in frontotemporal lobar degeneration.

Irwin DJ, Lleó A, Xie SX, McMillan CT, Wolk DA, Lee EB, Van Deerlin VM, Shaw LM, Trojanowski JQ, Grossman M.

Ann Neurol. 2017 Aug;82(2):247-258. doi: 10.1002/ana.24996. Epub 2017 Aug 19.

42.

Association analysis of rare variants near the APOE region with CSF and neuroimaging biomarkers of Alzheimer's disease.

Nho K, Kim S, Horgusluoglu E, Risacher SL, Shen L, Kim D, Lee S, Foroud T, Shaw LM, Trojanowski JQ, Aisen PS, Petersen RC, Jack CR Jr, Weiner MW, Green RC, Toga AW, Saykin AJ; Alzheimer’s Disease Neuroimaging Initiative (ADNI).

BMC Med Genomics. 2017 May 24;10(Suppl 1):29. doi: 10.1186/s12920-017-0267-0.

43.

Plasma Tau Association with Brain Atrophy in Mild Cognitive Impairment and Alzheimer's Disease.

Deters KD, Risacher SL, Kim S, Nho K, West JD, Blennow K, Zetterberg H, Shaw LM, Trojanowski JQ, Weiner MW, Saykin AJ; Alzheimer Disease Neuroimaging Initiative.

J Alzheimers Dis. 2017;58(4):1245-1254. doi: 10.3233/JAD-161114.

44.

RUNX1 and breast cancer.

Mercado-Matos J, Matthew-Onabanjo AN, Shaw LM.

Oncotarget. 2017 Jun 6;8(23):36934-36935. doi: 10.18632/oncotarget.17249. No abstract available.

45.

Night-Break Experiments Shed Light on the Photoperiod1-Mediated Flowering.

Pearce S, Shaw LM, Lin H, Cotter JD, Li C, Dubcovsky J.

Plant Physiol. 2017 Jun;174(2):1139-1150. doi: 10.1104/pp.17.00361. Epub 2017 Apr 13.

46.

Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials.

Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack CR Jr, Jagust W, Morris JC, Petersen RC, Saykin AJ, Shaw LM, Toga AW, Trojanowski JQ; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2017 Apr;13(4):e1-e85. doi: 10.1016/j.jalz.2016.11.007. Epub 2017 Mar 22. Review.

PMID:
28342697
47.

Metabolic network failures in Alzheimer's disease: A biochemical road map.

Toledo JB, Arnold M, Kastenmüller G, Chang R, Baillie RA, Han X, Thambisetty M, Tenenbaum JD, Suhre K, Thompson JW, John-Williams LS, MahmoudianDehkordi S, Rotroff DM, Jack JR, Motsinger-Reif A, Risacher SL, Blach C, Lucas JE, Massaro T, Louie G, Zhu H, Dallmann G, Klavins K, Koal T, Kim S, Nho K, Shen L, Casanova R, Varma S, Legido-Quigley C, Moseley MA, Zhu K, Henrion MYR, van der Lee SJ, Harms AC, Demirkan A, Hankemeier T, van Duijn CM, Trojanowski JQ, Shaw LM, Saykin AJ, Weiner MW, Doraiswamy PM, Kaddurah-Daouk R; Alzheimer's Disease Neuroimaging Initiative and the Alzheimer Disease Metabolomics Consortium.

Alzheimers Dement. 2017 Sep;13(9):965-984. doi: 10.1016/j.jalz.2017.01.020. Epub 2017 Mar 22.

48.

Differential involvement of the microtubule cytoskeleton in insulin receptor substrate 1 (IRS-1) and IRS-2 signaling to AKT determines the response to microtubule disruption in breast carcinoma cells.

Mercado-Matos J, Clark JL, Piper AJ, Janusis J, Shaw LM.

J Biol Chem. 2017 May 12;292(19):7806-7816. doi: 10.1074/jbc.M117.785832. Epub 2017 Mar 20.

49.

Genome-wide association study identifies four novel loci associated with Alzheimer's endophenotypes and disease modifiers.

Deming Y, Li Z, Kapoor M, Harari O, Del-Aguila JL, Black K, Carrell D, Cai Y, Fernandez MV, Budde J, Ma S, Saef B, Howells B, Huang KL, Bertelsen S, Fagan AM, Holtzman DM, Morris JC, Kim S, Saykin AJ, De Jager PL, Albert M, Moghekar A, O'Brien R, Riemenschneider M, Petersen RC, Blennow K, Zetterberg H, Minthon L, Van Deerlin VM, Lee VM, Shaw LM, Trojanowski JQ, Schellenberg G, Haines JL, Mayeux R, Pericak-Vance MA, Farrer LA, Peskind ER, Li G, Di Narzo AF; Alzheimer’s Disease Neuroimaging Initiative (ADNI); Alzheimer Disease Genetic Consortium (ADGC), Kauwe JS, Goate AM, Cruchaga C.

Acta Neuropathol. 2017 May;133(5):839-856. doi: 10.1007/s00401-017-1685-y. Epub 2017 Feb 28.

50.

BACE1 Dynamics Upon Inhibition with a BACE Inhibitor and Correlation to Downstream Alzheimer's Disease Markers in Elderly Healthy Participants.

Timmers M, Barão S, Van Broeck B, Tesseur I, Slemmon J, De Waepenaert K, Bogert J, Shaw LM, Engelborghs S, Moechars D, Mercken M, Van Nueten L, Tritsmans L, de Strooper B, Streffer JR.

J Alzheimers Dis. 2017;56(4):1437-1449. doi: 10.3233/JAD-160829.

Supplemental Content

Support Center